OBJECTIVE:Persons with schizophrenia die earlier than the general population, in large part due to cardiovascular disease. The study objective was to examine effects of different antipsychotic treatments on estimates of 10-year coronary heart disease (CHD) risk calculated by the Framingham Heart Study formula. METHOD: Change in 10-year risk for CHD was compared between treatment groups in 1125 patients followed for 18 months or until treatment discontinuation in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial. RESULTS: The covariate-adjusted mean change in 10-year CHD risk differed significantly between treatments. Olanzapine was associated with a 0.5% (SE 0.3) increase and quetiapine, a 0.3% (SE 0.3) increase; whereas risk decreased in patients treated with perphenazine, -0.5% (SE 0.3), risperidone, -0.6% (SE 0.3), and ziprasidone -0.6% (SE 0.4). The difference in 10-year CHD risk between olanzapine and risperidone was statistically significant (p=0.004). Differences in estimated 10-year CHD risk between drugs were most marked in the tertile of subjects with a baseline CHD risk of at least 10%. Among individual CHD risk factors used in the Framingham formula, only total and HDL cholesterol levels differed between treatments. CONCLUSIONS: These results indicate that the impact on 10-year CHD risk differs significantly between antipsychotic agents, with olanzapine producing the largest elevation in CHD risk of the agents studied in CATIE.
RCT Entities:
OBJECTIVE:Persons with schizophrenia die earlier than the general population, in large part due to cardiovascular disease. The study objective was to examine effects of different antipsychotic treatments on estimates of 10-year coronary heart disease (CHD) risk calculated by the Framingham Heart Study formula. METHOD: Change in 10-year risk for CHD was compared between treatment groups in 1125 patients followed for 18 months or until treatment discontinuation in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial. RESULTS: The covariate-adjusted mean change in 10-year CHD risk differed significantly between treatments. Olanzapine was associated with a 0.5% (SE 0.3) increase and quetiapine, a 0.3% (SE 0.3) increase; whereas risk decreased in patients treated with perphenazine, -0.5% (SE 0.3), risperidone, -0.6% (SE 0.3), and ziprasidone -0.6% (SE 0.4). The difference in 10-year CHD risk between olanzapine and risperidone was statistically significant (p=0.004). Differences in estimated 10-year CHD risk between drugs were most marked in the tertile of subjects with a baseline CHD risk of at least 10%. Among individual CHD risk factors used in the Framingham formula, only total and HDL cholesterol levels differed between treatments. CONCLUSIONS: These results indicate that the impact on 10-year CHD risk differs significantly between antipsychotic agents, with olanzapine producing the largest elevation in CHD risk of the agents studied in CATIE.
Authors: D B Allison; K R Fontaine; M Heo; J L Mentore; J C Cappelleri; L P Chandler; P J Weiden; L J Cheskin Journal: J Clin Psychiatry Date: 1999-04 Impact factor: 4.384
Authors: Gail L Daumit; Richard W Goldberg; Christopher Anthony; Faith Dickerson; Clayton H Brown; Julie Kreyenbuhl; Karen Wohlheiter; Lisa B Dixon Journal: J Nerv Ment Dis Date: 2005-10 Impact factor: 2.254
Authors: Donna A Wirshing; Jennifer A Boyd; Laura R Meng; Jacob S Ballon; Stephen R Marder; William C Wirshing Journal: J Clin Psychiatry Date: 2002-10 Impact factor: 4.384
Authors: Megan C Del Valle; Antony D Loebel; Stephen Murray; Ruoyong Yang; David J Harrison; Brian J Cuffel Journal: Prim Care Companion J Clin Psychiatry Date: 2006
Authors: Gail L Daumit; Jeanne M Clark; Donald M Steinwachs; Camelia M Graham; Anthony Lehman; Daniel E Ford Journal: J Nerv Ment Dis Date: 2003-12 Impact factor: 2.254
Authors: Stephen R Marder; Susan M Essock; Alexander L Miller; Robert W Buchanan; Daniel E Casey; John M Davis; John M Kane; Jeffrey A Lieberman; Nina R Schooler; Nancy Covell; Scott Stroup; Ellen M Weissman; Donna A Wirshing; Catherine S Hall; Leonard Pogach; Xavier Pi-Sunyer; J Thomas Bigger; Alan Friedman; David Kleinberg; Steven J Yevich; Bonnie Davis; Steven Shon Journal: Am J Psychiatry Date: 2004-08 Impact factor: 18.112
Authors: Kimberly R Warren; M Patricia Ball; Stephanie Feldman; Fang Liu; Robert P McMahon; Deanna L Kelly Journal: Biol Res Nurs Date: 2010-12-30 Impact factor: 2.522
Authors: Hua Jin; David Folsom; Alana Sasaki; Sunder Mudaliar; Robert Henry; Monique Torres; Shah Golshan; Danielle K Glorioso; Dilip Jeste Journal: Schizophr Res Date: 2010-11-19 Impact factor: 4.939
Authors: Stephanie A Flowers; Nielson T Baxter; Kristen M Ward; A Zarina Kraal; Melvin G McInnis; Thomas M Schmidt; Vicki L Ellingrod Journal: Pharmacotherapy Date: 2019-02-03 Impact factor: 4.705
Authors: Christina Mangurian; Chelsea Modlin; Lindsey Williams; Susan Essock; Nicholas S Riano; Martha Shumway; John W Newcomer; James W Dilley; Dean Schillinger Journal: Community Ment Health J Date: 2017-11-28
Authors: Maithri Prabhakar; William G Haynes; William H Coryell; Elizabeth A Chrischilles; Del D Miller; Stephan Arndt; Vicki L Ellingrod; Lois Warren; Jess G Fiedorowicz Journal: Pharmacotherapy Date: 2011-08 Impact factor: 4.705
Authors: T Scott Stroup; Matthew J Byerly; Henry A Nasrallah; Neepa Ray; Ahsan Y Khan; J Steven Lamberti; Ira D Glick; Richard M Steinbook; Joseph P McEvoy; Robert M Hamer Journal: Schizophr Res Date: 2013-02-21 Impact factor: 4.939
Authors: Nicolas M Furiak; Haya Ascher-Svanum; Robert W Klein; Lee J Smolen; Anthony H Lawson; Robert R Conley; Steven D Culler Journal: Cost Eff Resour Alloc Date: 2009-04-07